About Biogen
Biogen is a company based in Cambridge (United States) founded in 1978 by Heinz, Phillip Allen Sharp, Walter Gilbert, and Charles Weissmann. It operates as a Direct-to-Consumer (D2C), and Professional Services. Biogen has raised $80 million across 2 funding rounds from investors including PRIMECAP. The company has 7,610 employees as of December 31, 2024. Biogen has completed 11 acquisitions, including Conforma, Convergence Pharma and Fumapharm. Biogen offers products and services including Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions. Biogen operates in a competitive market with competitors including Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, ADMA Biologics and Biohaven Pharmaceutical, among others.
- Headquarter Cambridge, United States
- Employees 7610 as on 31 Dec, 2024
- Founders Heinz, Phillip Allen Sharp, Walter Gilbert, Charles Weissmann
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biogen Inc.
-
Annual Revenue
$9.27 B-1.6as on Dec 31, 2024
-
Net Profit
$1.63 B40.57as on Dec 31, 2024
-
EBITDA
$2.8 B31.57as on Dec 31, 2024
-
Total Equity Funding
$80 M (USD)
in 2 rounds
-
Latest Funding Round
- Investors
-
Employee Count
7610
as on Dec 31, 2024
-
Investments & Acquisitions
Conforma
& 10 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biogen
Biogen is a publicly listed company on the NASDAQ with ticker symbol BIIB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biogen
Biogen offers a comprehensive portfolio of products and services, including Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapies for Alzheimer's disease are developed and provided.
Treatments for multiple sclerosis are researched and offered.
Solutions for spinal muscular atrophy are created and distributed.
Unlock access to complete
Unlock access to complete
Software Development Team
228 people
Leadership Team
166 people
Senior Team
48 people
Data Analysis and Operations Team
41 people
Sales and Marketing
40 people
Product Management Team
38 people
Human Resources and Administration
38 people
Head Team
37 people
Unlock access to complete
Funding Insights of Biogen
Biogen has successfully raised a total of $80M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(19 Feb 1983)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Post-IPO - Biogen | Valuation |
investors |
|
| Feb, 1983 | Amount | Private Equity Round - Biogen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Biogen
Biogen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PRIMECAP. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manages mutual funds through fundamental stock selection and long-term horizons.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biogen
Biogen has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Conforma, Convergence Pharma and Fumapharm. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Precision medicines for autoimmune and inflammatory diseases are developed.
|
2021 | ||||
|
Gene therapies for inherited retinal diseases are developed.
|
2013 | ||||
|
Novel analgesics are developed for chronic pain via ion-channel modulation.
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Biogen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biogen Comparisons
Competitors of Biogen
Biogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, ADMA Biologics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biogen
Frequently Asked Questions about Biogen
When was Biogen founded?
Biogen was founded in 1978 and raised its 1st funding round 5 years after it was founded.
Where is Biogen located?
Biogen is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Biogen?
Christopher Viehbacher is the current CEO of Biogen.
Is Biogen a funded company?
Biogen is a funded company, having raised a total of $80M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $80M, raised on Feb 19, 1983.
How many employees does Biogen have?
As of Dec 31, 2024, the latest employee count at Biogen is 7,610.
What is the annual revenue of Biogen?
Annual revenue of Biogen is $9.27B as on Dec 31, 2024.
What does Biogen do?
Biogen is focused on the research and development of innovative therapies for neurological and neurodegenerative diseases. Areas of expertise include Alzheimers disease, multiple sclerosis, and spinal muscular atrophy. Solutions are provided through clinical trials and early access programs. The company operates globally, addressing health equity and access. Sectors served include biotechnology and healthcare with a commitment to transformative medicines.
Who are the top competitors of Biogen?
Biogen's top competitors include Jazz Pharmaceuticals, ADMA Biologics and PTC Therapeutics.
What products or services does Biogen offer?
Biogen offers Alzheimer's Disease Therapies, Multiple Sclerosis Treatments, and Spinal Muscular Atrophy Solutions.
Is Biogen publicly traded?
Yes, Biogen is publicly traded on NASDAQ under the ticker symbol BIIB.
How many acquisitions has Biogen made?
Biogen has made 11 acquisitions, including Conforma, Convergence Pharma, and Fumapharm.
Who are Biogen's investors?
Biogen has 1 investor. Key investors include PRIMECAP.
What is Biogen's ticker symbol?
The ticker symbol of Biogen is BIIB on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.